Nyxoah SA (FRA:5YI)

Market Cap	169.95M -56.5%
Revenue (ttm)	5.64M +11.0%
Net Income	-83.72M
EPS	-2.24
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	191
Open	3.845
Previous Close	3.975
Day's Range	3.755 - 3.845
52-Week Range	3.560 - 10.600
Beta	n/a
RSI	47.40
Earnings Date	Mar 19, 2026

About Nyxoah

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 2009
• Employees: 184
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5YI

Financial Performance

In 2024, Nyxoah's revenue was 4.52 million, an increase of 3.98% compared to the previous year's 4.35 million. Losses were -59.24 million, 37.1% more than in 2023.